Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apitegromab in Facioscapulohumeral Muscular Dystrophy (FORGE)
NCT07435129Phase 2Recruiting
- Sponsor
- Scholar Rock
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of apitegromab in facioscapulohumeral muscular dystrophy (FSHD), sponsored by Scholar Rock. Started Jul 2026; status: recruiting.
02
Drugs
apitegromab
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT07435129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07435129.